R&D

From 1996 to 2011 the core competence of MT was centered on the Discovery and the pre-clinical/clinical development of novel molecules, acting as photosensitizers for PhotoDynamic Therapy (PDT) therapy. This initial effort generated an innovative Photodynamic sensitizers platform aimed at the treatment of unmet medical need in the wound care. The identification of several lead candidates and the in-depth study of their characteristics provide a safe and effective tool for improving different types of recalcitrant and chronic ulcers as well as different therapeutic areas of infectious disease.

Also enabled Molteni Therapeutics to create a strong intellectual property position around all compounds and their medical applications in different uses of PDT.